FGFR2 Antibody - #AF0159

Figure 3.Autophagy inhibition promotes tenogenic differentiation of tension-treated CDSCs through activation of FGF signaling. (A) PCR analysis of tenogenic differentiation-related signaling pathways of CDSCs in each group (n = 3). (B) Western Blot analysis for FGF signaling. (C) Cell morphology of CDSCs in Ten + AZD and Ten + CQ + AZD groups. Ten + AZD, cyclic tensile tress and AZD4547 (100 nM/L) treated CDSCs; Ten + CQ + AZD, cyclic tensile tress, chloroquine and AZD4547 treated CDSCs. (D) Fluorescent images of autophagy flux in Ten + AZD and Ten + CQ + AZD groups. Scale bar = 50 μm. (E) TEM images of autophagosomes in Ten + AZD and Ten + CQ + AZD groups. Scale bar = 50 μm. Merged GFP and RFP dots indicate autophagosomes. (F) Western Blot analysis for the autophagy-related markers in each group. (G-I) PCR (G) and Western Blot (H,I) analyses for the tenogenic, chondrogenic-related markers and Fgfr2, Fgf2 (n = 3). Data are mean ± S.D. *, P 

FIGURE 7| The effects of lncRNA FAF, FGF9, and FGFR2 in cardiomyocytes and heart tissues. (a,b) The FGF9 mRNA and the protein expression level were measured by RT‐PCR and western blot analysis in ischemia–hypoxia cardiomyocytes and control groups. (c,d) The results of FGF9 mRNA and protein expression level in AMI rats and healthy controls on RT‐PCR and western blot analysis analysis.(e) The expression level of FGF9 was measured in the plasma of patients with AMI and healthy groups (N = 20). (f,g) The results of FGF9 mRNA and protein expression level in cardiomyocytes after overexpression of lncRNA FAF. (h,i) RT‐PCR and western blot analysis of FGFR2 in ischemia–hypoxia cardiomyocytes and control groups.

Fig. 2. Effects of LRG on adipocyte size and the protein expression in WAT of diabetic mice. (A) Adipocyte size of the mice; (B) Quantification of Fig. 2A; (C) Immunohistochemical assay of WAT; (D) Quantification of Fig. 2C; (E) Protein expression in WAT; (F) Quantification of Fig. 3E n ¼ 6 mice/group. #p < 0.05, ##p < 0.01,###p < 0.001 vs CON; *p < 0.05,**p < 0.01, ***p < 0.001 vs DM.

Figure 3 Verification of the regulatory effect of chi-mir-370-3p on TGF-βR2 and FGFR2 at epithelial cell and dermal fibroblast levels. (A) Construction of chi-miR-370-3p (lo) and chi-miR-370-3p (hi) dermal fibroblast and epithelial cell lines. (B) Relative expression of chi-miR-370-3p in various cell lines. (C) Relative expression of TGF-βR2 and FGFR2 in various cell lines. (D) Expression of β-actin, TGF-βR2, and FGFR2 proteins in each cell line. (E) Relative abundance of TGF-βR2 and FGFR2 proteins in different epithelial cell lines. (F) Relative abundance of TGF-βR2 and FGFR2 proteins in different dermal fibroblast cell lines.